Shattuck Labs (STTK) Expected to Announce Earnings on Wednesday

Shattuck Labs (NASDAQ:STTK) will likely be posting its earnings results on Wednesday, February 26th. Analysts expect Shattuck Labs to post earnings of ($0.32) per share and revenue of $1.00 million for the quarter.

Shattuck Labs Trading Down 5.3 %

Shares of NASDAQ:STTK opened at $1.26 on Wednesday. The firm has a market cap of $60.15 million, a price-to-earnings ratio of -0.82 and a beta of 1.70. The stock’s 50-day moving average price is $1.19 and its two-hundred day moving average price is $1.88. Shattuck Labs has a 12-month low of $0.94 and a 12-month high of $11.76.

Insider Transactions at Shattuck Labs

In other Shattuck Labs news, Director Redmile Group, Llc bought 133,371 shares of Shattuck Labs stock in a transaction that occurred on Wednesday, December 4th. The shares were acquired at an average price of $1.25 per share, for a total transaction of $166,713.75. Following the acquisition, the director now owns 5,539,724 shares of the company’s stock, valued at $6,924,655. The trade was a 2.47 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 10.50% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on STTK shares. HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a research report on Friday, November 15th. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a report on Thursday, November 14th. Four research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Shattuck Labs presently has a consensus rating of “Hold” and a consensus target price of $8.67.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.